Suven Life Sciences Limited (NSE:SUVEN)
India · Delayed Price · Currency is INR 278.25
-1.70 (-0.61%)
Nov 11, 2026, 1:14 PM IST
Suven Life Sciences Revenue
Suven Life Sciences had revenue of 79.33M INR in the quarter ending September 30, 2026, with 763.03% growth. This brings the company's total for the last twelve months to 189.73M, up 223.62% year-over-year. In the fiscal year ending March 31, 2026, Suven Life Sciences had annual revenue of 71.15M with 6.89% growth.
Revenue (ttm)
189.73M
Revenue Growth
+223.62%
P/S Ratio
416.84
Revenue / Employee
1.34M
Employees
142
Market Cap
78.72B
Revenue by Geography
- United States of America (USA) 25.11M 35.3%
- India 21.57M 30.3%
- Europe 15.31M 21.5%
- Rest of the World 9.15M 12.9%
Fiscal year ended Mar 31, 2026 See the full Suven Life Sciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 71.15M | 4.59M | 6.89% |
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Strides Pharma Science | 52.13B |
| Akums Drugs and Pharmaceuticals | 48.29B |
| NATCO Pharma | 34.85B |
| Eris Lifesciences | 33.12B |
| Cohance Lifesciences | 20.57B |
| Aarti Pharmalabs | 19.69B |
| Sun Pharma Advanced Research Company | 19.32B |
| Innova Captab | 17.49B |
Suven Life Sciences News
- 4 months ago - Suven Life Sciences allots 1.85 crore shares on preferential basis for Rs 248.84 crore - Business Upturn
- 4 months ago - Suven Life Sciences raises ₹248.84 crore through preferential allotment - Business Upturn
- 4 months ago - Suven Life Sciences to showcase CNS clinical candidates at BIO-2026 in San Diego - Business Upturn
- 4 months ago - Suven Life Sciences reports positive results from Ropanicant Phase-2b trial for depression - Business Upturn
- 4 months ago - Suven Life Sciences successfully completes Phase-1 Clinical Trial of SUVN-I6107 for CNS disorders - Business Upturn
- 5 months ago - Suven Life Sciences to present Phase-3 narcolepsy study at SLEEP-2026 - Business Upturn
- 5 months ago - Suven Life Sciences reports positive DSMB review in Alzheimer's study - Business Upturn
- 5 months ago - Suven Life Sciences shares rally over 17% today; Details here - Business Upturn